IP Group PLC has invested £4 million in a £36 million Series C funding round for Microbiotica, supporting the development of its ulcerative colitis treatment, MB310. The funding, led by British Business Bank, will enable Microbiotica to progress MB310 into Phase 2 clinical trials after positive Phase 1b results showing significant clinical remission. Following this round, IP Group holds a 16.4% stake in Microbiotica, valued at £24.1 million. Microbiotica, spun out from the Wellcome Sanger Institute, also develops other treatments including MB097 for advanced melanoma, currently in Phase 1b trials with Merck's KEYTRUDA.
Microbiotica's recent £36 million funding round included a £4 million investment from IP Group, which now holds a 16.4% stake valued at £24.1 million. For readers following health sector stocks, here is Pluang's market snapshot as of Oct 16, 2026 12:11 WIB: out of 150 priced US health stocks, 122 rose and 26 fell. Notable movers include ALNY at USD 235.58 (+4.95%), XRAY at USD 8.84 (+4.74%) with 100% sell order activity, and SANA at USD 2.44 (+4.72%) with 76% sell orders and 24% buys, typical hold times ranging from 24 to 73 days.
UBS Group AG has officially notified that it holds 7,768,727 shares in Bang & Olufsen A/S, representing 5.27% of the company's total share capital and voting rights as of October 9, 2026. This disclosure is made in compliance with the Danish Capital ...
On October 14, 2026, Michael Brierley, a Non-Executive Director of Admiral Group plc, and his wife Rachel Brierley acquired shares of the company through a dividend reinvestment trading plan. The transactions involved purchasing ordinary shares at pr...
Norsk Hydro will publish its third-quarter 2026 financial results on October 23, 2026, at 07:00 CEST. The company's CEO and CFO will present the results via a live webcast at 08:30 CEST the same day, allowing investors to ask questions online. There ...
The FDA has approved Roche's Enspryng (satralizumab) as the first and only at-home subcutaneous treatment for adults with thyroid eye disease (TED). This approval follows positive results from Phase III SatraGO-2 trials showing significant reductions...
Tesla's Q3 earnings report, due October 21, will show if stronger-than-expected vehicle deliveries and growth in energy storage can balance challenges in its automotive segment. The company produced 464,391 vehicles and delivered 486,532, slightly do...
